Find out more …

Filter results
E.g., 21/04/2019
E.g., 21/04/2019
ROVI will market Teva's medicine Tetridar® for the treatment of osteoporosis in adults in Spain
Advanced Final Results from the Pivotal Study of its Once-monthly Injectable Antipsychotic show that Primary and Key Secondary Efficacy Endpoints Were Achieved with Both Doses Tested for the Treatment of Patients with Acute Exacerbation of Schizophrenia
Download our press release published on 26 February to find out the financial results for the full year 2018.